Search Results - "Petros, W P"

Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support by RIZZIERI, D. A, VREDENBURGH, J. J, AFFRONTI, M. L, CONIGLIO, D, RUBIN, P, ELKORDY, M, LONG, G. D, CHAO, N. J, PETERS, W. P, JONES, R, ROSS, M, SHPALL, E. J, HUSSEIN, A, BROADWATER, G, BERRY, D, PETROS, W. P, GILBERT, C

“…We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy,…”
Get full text

Phase I/II trial of intravenous Doxil and whole abdomen hyperthermia in patients with refractory ovarian cancer by Alvarez Secord, A, Jones, E L, Hahn, C A, Petros, W P, Yu, D, Havrilesky, L J, Soper, J T, Berchuck, A, Spasojevic, I, Clarke-Pearson, D L, Prosnitz, L R, Dewhirst, M W

“…A phase I/II study of Doxil combined with whole abdomen hyperthermia was conducted in patients with refractory ovarian cancer. Liposomal doxorubicin combined…”
Get more information

Transforming Growth Factor β as a Predictor of Liver and Lung Fibrosis after Autologous Bone Marrow Transplantation for Advanced Breast Cancer by Anscher, Mitchell S, Peters, William P, Reisenbichler, Herbert, Petros, William P, Jirtle, Randy L

“…Hepatic veno-occlusive disease is a serious consequence of high-dose chemotherapy or radiotherapy combined with bone marrow transplantation for neoplasia; it…”
Get full text

Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer by WILCZYNSKI, S. W, ERASMUS, J. J, PETROS, W. P, VREDENBURGH, J. J, FOLZ, R. J

“…We have intensely followed 45 consecutive women who underwent high-dose chemotherapy (cyclophosphamide/cisplatin/BCNU) and autologous bone marrow transplant…”
Get full text

Phase I study of Doxil and vinorelbine in metastatic breast cancer by BURSTEIN, H. J, RAMIREZ, M. J, PETROS, W. P, CLARKE, K. D, WARMUTH, M. A, MARCOM, P. K, MATULONIS, U. A, PARKER, L. M, HARRIS, L. N, WINER, E. P

“…Vinorelbine and Doxil (liposomal doxorubicin) are active chemotherapeutic agents in metastatic breast cancer. A phase I study was designed to evaluate…”
Get full text

Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support by BHALLA, K. S, WILCZYNSKI, S. W, ABUSHAMAA, A. M, PETROS, W. P, MCDONALD, C. S, LOFTIS, J. S, CHAO, N. J, VREDENBURGH, J. J, FOLZ, R. J

“…We closely followed the pulmonary function of 150 consecutive high-risk breast cancer patients who underwent standard induction CAF (cyclophosphamide,…”
Get full text

Efficacy of liposomes and hyperthermia in a human tumor xenograft model : Importance of triggered drug release by GARHENG KONG, ANYARAMBHATLA, Gopal, PETROS, William P, BRAUN, Rod D, COLVIN, O. Michael, NEEDHAM, David, DEWHIRST, Mark W

“…The tumor drug concentrations, drug distributions, and therapeutic efficacies achieved by three fundamentally different liposomes, nonthermosensitive liposome…”
Get full text

Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies by Ochoa, L., Hurwitz, H. I., Wilding, G., Cohen, D., Thomas, J. P., Schwartz, G., Monroe, P., Petros, W. P., Ertel, V. Ph, Hsieh, A., Hoffman, C., Drengler, R., Magnum, S., Rowinsky, E. K.

“…Background: This study was performed to evaluate the pharmacokinetics, bioequivalence, and feasibility of a combined oral formulation of 5-flurouracil (5-FU)…”
Get full text

Pharmacokinetic studies with recombinant cytokines : Scientific issues and practical considerations by PISCITELLI, S. C, REISS, W. G, FIGG, W. D, PETROS, W. P

“…Advances in molecular biology and recombinant DNA technology have led to the development of cytokines as therapeutic agents for a variety of disease states…”
Get full text

Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease by PERRY, J. J, FLEMING, R. A, ROCCO, M. V, PETROS, W. P, BLEYER, A. J, RADFORD, J. E, POWELL, B. L, HURD, D. D

“…We report a patient with pre-existing end-stage renal disease (ESRD) who underwent successful matched related donor allogeneic bone marrow transplantation for…”
Get full text

Pharmacokinetic interaction between ondansetron and cyclophosphamide during high-dose chemotherapy for breast cancer by GILBERT, C. J, PETROS, W. P, PETERS, W. P, VREDENBURGH, J, HUSSEIN, A, ROSS, M, RUBIN, P, FEHDRAU, R, CAVANAUGH, C, BERRY, D, MCKINSTRY, C

“…Both ondansetron and cyclophosphamide are thought to be metabolized by hepatic microsomal processes. The purpose of this study was to evaluate the potential…”
Get full text

Characterization of endogenous cytokine concentrations after high-dose chemotherapy with autologous bone marrow support by RABINOWITZ, J, PETROS, W. P, STUART, A. R, PETERS, W. P

“…Endogenous cytokines are thought to mediate numerous biologic processes and may account for some adverse effects experienced following the administration of…”
Get full text

Reduced mortality following bone marrow transplantation for breast cancer with the addition of peripheral blood progenitor cells is due to a marked reduction in veno-occlusive disease of the liver by FISHER, D. C, VREDENBURGH, J. J, PETROS, W. P, HUSSEIN, A, BERRY, D. A, ELKORDY, M, RUBIN, P, GILBERT, C. J, PETERS, W. P

“…Clinical trials involving breast cancer in the Duke University Bone Marrow Transplant Program were evaluated to assess the association between type of…”
Get full text

Metabolic jeopardy with high-dose cyclophosphamide?--not so fast by Petros, W P, Colvin, O M

Get full text

Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy by Furman, W L, Fairclough, D L, Huhn, R D, Pratt, C B, Stute, N, Petros, W P, Evans, W E, Bowman, L C, Douglass, E C, Santana, V M

“…Twenty-five children with refractory solid tumors were given recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in escalated doses…”
Get more information

Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer : a phase II trial by SUTTON, L. M, WARMUTH, M. A, PETROS, W. P, WINER, E. P

“…The purpose of this trial was to evaluate tumor cytoreduction by all-trans retinoic acid (ATRA) in patients with metastatic breast cancer and to characterize…”
Get full text

Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation by PETROS, W. P, RABINOWITZ, J, STUART, A, PETERS, W. P

“…We evaluated the pharmacokinetics and pharmacodynamics of filgrastim during a Phase I study of this cytokine following high-dose chemotherapy and autologous…”
Get full text

A phase I trial of recombinant human interleukin-1β (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation by ELKORDY, M, CRUMP, M, CONIGLIO, D, RABINOWITZ, J, LAUGHLIN, M, KURTZBERG, J, PETERS, W. P, VREDENBURGH, J. J, PETROS, W. P, HUSSEIN, A, RUBIN, P, ROSS, M, GILBERT, C, MODLIN, C, MEISENBERG, B

“…We studied the effects of escalating doses of recombinant human IL-1 beta in patients receiving high-dose chemotherapy and ABMT for metastatic breast cancer or…”
Get full text

Changes in plasma transforming growth factor beta in response to high-dose chemotherapy for stage II breast cancer: possible implications for the prevention of hepatic veno-occlusive disease and pulmonary drug toxicity by Murase, T, Anscher, M S, Petros, W P, Peters, W P, Jirtle, R L

“…Veno-occlusive disease (VOD) of the liver and pulmonary drug toxicity (PDT) are two major complications of high-dose chemotherapy and autologous bone marrow…”
Get more information

Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects by Relling, M V, Cherrie, J, Schell, M J, Petros, W P, Meyer, W H, Evans, W E

“…Our objective was to determine whether there are differences in debrisoquin hydroxylase (P450IID6) activity between American black subjects and white subjects…”
Get more information